SITC Resource Library

The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma 

08-26-2022 08:04

Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs)— either as monotherapy or in combination with other ICIs or chemotherapy—have demonstrated benefits in first-line therapy for advanced disease, the neoadjuvant and adjuvant settings, as well as in additional thoracic malignancies such as small-cell lung cancer (SCLC) and mesothelioma. Challenging questions remain, however, on topics including therapy selection, appropriate biomarker-based identification of patients who may derive benefit, the use of immunotherapy in special populations such as people with autoimmune disorders, and toxicity management. Patient and caregiver education and support for quality of life (QOL) is also important to attain maximal benefit with immunotherapy. To provide guidance to the oncology community on these and other important concerns, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). This CPG represents an update to SITC’s 2018 publication on immunotherapy for the treatment of NSCLC, and is expanded to include recommendations on SCLC and mesothelioma. The Expert Panel drew on the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for lung cancer and mesothelioma, including diagnostic testing, treatment planning, immune-related adverse events, and patient QOL considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers using immunotherapy to treat patients with lung cancer or mesothelioma.

Authors: Ramaswamy Govindan, Charu Aggarwal, Scott J Antonia, Marianne Davies, Steven M Dubinett, Andrea Ferris, Patrick M Forde, Edward B Garon, Sarah B Goldberg, Raffit Hassan, Matthew D Hellmann, Fred R Hirsch, Melissa L Johnson, Shakun Malik,Daniel Morgensztern, Joel W Neal, Jyoti D Patel, David L Rimm, Sarah Sagorsky, Lawrence H Schwartz, Boris Sepesi and Roy S Herbst
Published in the position article and guidelines section of the Journal for ImmunoTherapy of Cancer (2022) 10:5.
#SITCPublication
#ClinicalPracticeGuideline
#JournalforImmunoTherapyofCancer
#LungCancers
#Mesothelioma
#Clinician
#Pharmacist
#Oncologist
#ImmuneCheckpointInhibitors
#CombinationTherapy
#Biomarkers
#TherapeuticAntibodies
#Toxicities
#2022

Statistics
0 Favorited
7 Views
0 Files
0 Shares
0 Downloads

Related Entries and Links

No Related Resource entered.